Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

30:17
 
Share
 

Manage episode 513531254 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd.

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

add url

  continue reading

513 episodes

Artwork
iconShare
 
Manage episode 513531254 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd.

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

add url

  continue reading

513 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play